Top-Rated StocksTop-RatedNASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $24.49 -0.14 (-0.57%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$24.43▼$25.0750-Day Range$18.82▼$24.8152-Week Range$11.22▼$25.34Volume456,509 shsAverage Volume1.10 million shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/APrice Target$34.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Syndax Pharmaceuticals alerts: Email Address Syndax Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside41.8% Upside$34.73 Price TargetShort InterestBearish10.02% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.58Based on 4 Articles This WeekInsider TradingAcquiring Shares$25,038 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.49) to ($2.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.43 out of 5 starsMedical Sector127th out of 936 stocksPharmaceutical Preparations Industry47th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Syndax Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.02% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 2.16%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 3.1 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest2 people have searched for SNDX on MarketBeat in the last 30 days. MarketBeat Follows7 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,038.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.Read more about Syndax Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.49) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -7.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -7.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syndax Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesJuly 25 at 6:49 PM | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)July 25 at 7:00 AM | prnewswire.comSyndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024July 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 5, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 21, 2024 | seekingalpha.comSyndax: Gearing Up For LaunchesJune 14, 2024 | prnewswire.comSyndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 CongressJune 6, 2024 | prnewswire.comSyndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRCJune 5, 2024 | prnewswire.comSyndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare ConferenceJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 3, 2024 | prnewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Teva Pharmaceutical (TEVA), Cencora (COR)May 15, 2024 | prnewswire.comSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsMay 13, 2024 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Stifel NicolausMay 12, 2024 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comBuy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug CandidateMay 9, 2024 | finance.yahoo.comSyndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | prnewswire.comSyndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceMay 8, 2024 | msn.comSNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024See More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$34.73 High Stock Price Target$45.00 Low Stock Price Target$23.00 Potential Upside/Downside+41.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.32% Return on Assets-48.46% Debt Debt-to-Equity RatioN/A Current Ratio8.93 Quick Ratio8.93 Sales & Book Value Annual Sales$139.71 million Price / Sales14.90 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book3.75Miscellaneous Outstanding Shares84,990,000Free Float81,503,000Market Cap$2.08 billion OptionableOptionable Beta0.94 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 53)CEO & Director Comp: $1.1MDr. Peter Ordentlich B.Sc. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 67)Co-Founder Dr. Ronald M. Evans Ph.D. (Age 75)Co-Founder, Advisor and Chair of Scientific Advisory Board Dr. Michael Downes Ph.D.Co-FounderSharon KlahreVice President of Investor Relations & CommunicationsMr. Kevin McManus (Age 55)Chief People Officer Dr. Joseph Paul Eder M.D.Member of Scientific Advisory Board & Chief Medical OfficerDr. Anjali Ganguli Ph.D. (Age 47)Chief Business Officer Comp: $450.58kMr. Steven ClosterChief Commercial OfficerMore ExecutivesKey CompetitorsEnanta PharmaceuticalsNASDAQ:ENTADyne TherapeuticsNASDAQ:DYNRevolution MedicinesNASDAQ:RVMDSummit TherapeuticsNASDAQ:SMMTElanco Animal HealthNYSE:ELANView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 46,463 shares on 7/26/2024Ownership: 0.343%Assenagon Asset Management S.A.Bought 151,021 shares on 7/18/2024Ownership: 0.505%SG Americas Securities LLCBought 31,051 shares on 7/12/2024Ownership: 0.037%DNB Asset Management ASBought 3,804 shares on 7/5/2024Ownership: 0.015%Keith A GoldanBought 1,250 shares on 6/14/2024Total: $25,037.50 ($20.03/share)View All Insider TransactionsView All Institutional Transactions SNDX Stock Analysis - Frequently Asked Questions How have SNDX shares performed this year? Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of 2024. Since then, SNDX stock has increased by 13.3% and is now trading at $24.49. View the best growth stocks for 2024 here. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its earnings results on Wednesday, May, 8th. The company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.96) by $0.11. When did Syndax Pharmaceuticals IPO? Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.50%), Bank of New York Mellon Corp (0.34%), SG Americas Securities LLC (0.04%) and DNB Asset Management AS (0.02%). Insiders that own company stock include Dennis Podlesak, William Meury, Keith Katkin, Pierre Legault, Briggs Morrison, Michael A Metzger, Alexander Nolte, Peter Ordentlich and Fabrice Egros. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). This page (NASDAQ:SNDX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
